Narya Capital
VC Fund
Ohio, United States
Narya Capital is a VC fund in Ohio focused on AgTech and Agriculture. Narya is a thesis-driven, early-stage venture capital firm based in Ohio. Our LPs include some of the most successful investors, entrepreneurs, innovators and institutions in the world. We invest long term capital in people who use technology to solve significant challenges.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 13%
- Fund size:
- $93M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Narya Capital invests in
AgTechAgricultureHealth CareInformation TechnologyMachinery Manufacturing
Stages Narya Capital invests in
Series BSeries CSeries ASeedSeries D
Countries Narya Capital invests in
United StatesCanada
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Colin Greenspon
|
|||
Falon Donohue
|
|||
James David Vance
|
|||
2 more contacts available
Investment Focus
Industry
- AgTech 2 (7%)
- Agriculture 2 (7%)
- Health Care 2 (7%)
- Information Technology 2 (7%)
- Machinery Manufacturing 2 (7%)
Stage
- Series B 6 (20%)
- Series C 5 (17%)
- Series A 4 (13%)
- Seed 3 (10%)
- Series D 2 (7%)
Country
- United States 9 (30%)
- Canada 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Colin Greenspon
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 10 | Find email | |
|
Falon Donohue
Partner
|
Partner | Total investments: 2 | Find email | |
|
James David Vance
Co-Founder and Partner
|
Co-Founder and Partner | Total investments: 10 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beren Therapeutics
|
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA. | $135M / Venture - Series Unknown / Jun 10, 2026 | |
Reprogram Biosciences
|
Reprogram Biosciences is a biotechnology company that develops cancer treatment with cell reprogramming technology. | $5M / Seed / May 26, 2026 | |
True Anomaly
|
True Anomaly develops space security technologies, including spacecraft, software platforms, and mission systems for orbital operations. The company builds satellites and autonomous systems that support monitoring, maneuvering, and coordination in space environments. Its offerings include simulation tools and mission planning software that helpoperators model scenarios and manage on-orbit activities. The organization also provides hardware and integrated systems that enable responsive deployment and control of space assets. Its work focuses on supporting government and commercial missions that require situational awareness and operational capabilities beyond Earth. | $600M / Series D / Apr 28, 2026 | |
Chapter
|
Chapter provides a technology-enabled advisory platform that helps individuals navigate Medicare and retirement-related healthcare decisions. The company offers access to licensed advisors who guide users through plan selection, enrollment timing, and coverage evaluation based on individual needs and preferences. It uses data and software tools tocompare Medicare plans across multiple insurance providers, enabling users to review options and understand cost, coverage, and benefits. It supports decision-making by analyzing plan details and presenting recommendations that align with a user’s healthcare requirements and financial considerations. Its services include ongoing support after enrollment, helping individuals manage their coverage and make adjustments when necessary. The platform also provides digital tools, such as applications for tracking healthcare benefits and accessing over-the-counter allowances.Chapter collaborates with financial institutions, healthcare providers, and content platforms to integrate Medicare guidance into broader client and patient services. It delivers advisory support through partnerships, enabling organizations to offer healthcare coverage guidance as part of their existing offerings. The company combines advisory services with data analysis to simplify complex insurance decisions and assist users in understanding available Medicare options. Its operations focus on improving transparency in plan comparisons and supporting individuals throughout different stages of retirement healthcare planning. | $100M / Series E / Apr 09, 2026 | |
Valinor Enterprises
|
Valinor Enterprises develops technology solutions addressing operational challenges for defense customers. | $54M / Series A / Jan 08, 2026 | |
Peptilogics
|
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M / Series B / Oct 16, 2025 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $320.8M / Series D / Aug 15, 2025 | |
Atomic Industries
|
Atomic Industries is a computational manufacturing company building an AI-powered tool and die maker. | $25M / Series A / Jun 26, 2025 | |
|
True Anomaly
|
True Anomaly develops space security technologies, including spacecraft, software platforms, and mission systems for orbital operations. The company builds satellites and autonomous systems that support monitoring, maneuvering, and coordination in space environments. Its offerings include simulation tools and mission planning software that helpoperators model scenarios and manage on-orbit activities. The organization also provides hardware and integrated systems that enable responsive deployment and control of space assets. Its work focuses on supporting government and commercial missions that require situational awareness and operational capabilities beyond Earth. | $260M / Series C / Apr 30, 2025 | |
|
Chapter
|
Chapter provides a technology-enabled advisory platform that helps individuals navigate Medicare and retirement-related healthcare decisions. The company offers access to licensed advisors who guide users through plan selection, enrollment timing, and coverage evaluation based on individual needs and preferences. It uses data and software tools tocompare Medicare plans across multiple insurance providers, enabling users to review options and understand cost, coverage, and benefits. It supports decision-making by analyzing plan details and presenting recommendations that align with a user’s healthcare requirements and financial considerations. Its services include ongoing support after enrollment, helping individuals manage their coverage and make adjustments when necessary. The platform also provides digital tools, such as applications for tracking healthcare benefits and accessing over-the-counter allowances.Chapter collaborates with financial institutions, healthcare providers, and content platforms to integrate Medicare guidance into broader client and patient services. It delivers advisory support through partnerships, enabling organizations to offer healthcare coverage guidance as part of their existing offerings. The company combines advisory services with data analysis to simplify complex insurance decisions and assist users in understanding available Medicare options. Its operations focus on improving transparency in plan comparisons and supporting individuals throughout different stages of retirement healthcare planning. | $75M / Series D / Apr 16, 2025 | |
| See all 30 investments → | |||
Co-Investors
Susa Ventures
6 deals together
XYZ Venture Capital
6 deals together
Maverick Ventures
5 deals together
Patient Square Capital
5 deals together
Addition
4 deals together
Eclipse
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Agriculture (agtech) Investors
10,346 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
FAQ
What does Narya Capital invest in?
Narya Capital invests primarily in AgTech, Agriculture and Health Care startups, most often at Series B and Series C stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Narya Capital?
Public channels for Narya Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Narya Capital?
The team at Narya Capital includes Colin Greenspon (Co-Founder & Partner), Falon Donohue (Partner) and James David Vance (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
